<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02279524</url>
  </required_header>
  <id_info>
    <org_study_id>Aramchol005</org_study_id>
    <nct_id>NCT02279524</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH</brief_title>
  <acronym>Aramchol_005</acronym>
  <official_title>A Phase IIb, Double Blind Randomized, Controlled Clinical Trial, to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) - Aramchol 005 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galmed Research and Development, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sharp Clinical Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diamond Pharma Services Regulatory Affairs Consultancy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ClinIntel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Itamar-Medical, Israel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>One Way Liver OWL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DSG EDC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TransPerfect</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Reference Laboratory</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Galmed Pharmaceuticals Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, Phase IIb, randomized, double blind, placebo-controlled study designed&#xD;
      to evaluate the efficacy and safety of two Aramchol doses in subjects that are 18 to 75 years&#xD;
      of age, with Non-Alcoholic Steatohepatitis (NASH) confirmed by liver biopsy performed in a&#xD;
      period of 6 months before entering the study, with overweight or obesity and who are pre&#xD;
      diabetic or type II diabetic.&#xD;
&#xD;
      Eligible subjects will be enrolled into three treatments arms: Aramchol 400 and 600 mg&#xD;
      tablets and placebo tablets in ratio 2:2:1.&#xD;
&#xD;
      The subjects will be evaluated at study sites for 11 scheduled visits during one year (52&#xD;
      weeks). After completion of the study treatment period, the subjects will be followed for an&#xD;
      additional period of 13 weeks without study medication (until visit 11 (week 65)).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, Phase IIb, randomized, double blind, placebo-controlled study designed&#xD;
      to evaluate the efficacy and safety of two Aramchol doses in subjects that are 18 to 75 years&#xD;
      of age, with Non-Alcoholic Steatohepatitis (NASH) confirmed by liver biopsy performed in a&#xD;
      period of 6 months before entering the study, with overweight or obesity and who are pre&#xD;
      diabetic or type II diabetic.&#xD;
&#xD;
      Eligible subjects will be enrolled into three treatments arms: Aramchol 400 and 600 mg&#xD;
      tablets and placebo tablets in ratio 2:2:1.&#xD;
&#xD;
      The subjects will be evaluated at study sites for 11 scheduled visits: at screening (visit&#xD;
      1(weeks -4 - 0)), baseline (visit 2 (day 0)), visit 3 (week 2), visit 4 week 4), visit 5&#xD;
      (week 8), visit 6 (week 12), visit 7 (week 24), visit 8 (week 32), visit 9 (week 40) and&#xD;
      visit 10 (week 52 - (End of Treatment/early termination visit)). After completion of the&#xD;
      study treatment period, the subjects will be followed for an additional period of 13 weeks&#xD;
      without study medication (until visit 11 (week 65)).&#xD;
&#xD;
      During the screening period, the severity of the disease will be evaluated with blood tests,&#xD;
      liver biopsy and NMRS.&#xD;
&#xD;
      During the study the following assessments will be performed:&#xD;
&#xD;
        -  Vital signs will be measured at each study visit.&#xD;
&#xD;
        -  A physical examination will be performed at the screening visit, 24 weeks, End of&#xD;
           Treatment/early termination and week 65 visit.&#xD;
&#xD;
      The following blood tests will be performed: complete blood count (CBC), serum chemistry&#xD;
      (including electrolytes, liver enzymes, direct and total bilirubin, glucose, lipid profile&#xD;
      which include triglyceride, cholesterol, HDL, LDL and VLDL, CPK, creatinine, urea, albumin,&#xD;
      alkaline phosphatase), ESR and urinalysis during the screening visit, baseline, week 2, 4, 8,&#xD;
      24, 40, 52 and 65 (end of follow up) visits. Serology (HBV, HCV and HIV) will be performed&#xD;
      during the screening visit. Coagulation (fibrinogen, PT/INR, aPTT) will be measured during&#xD;
      screening and at baseline, week 24, End of Treatment/early termination and week 65 visits.&#xD;
      Insulin (HOMA) will be measured during the screening, at week 24 and End of Treatment/early&#xD;
      termination visits. HbA1C will be measured during the screening, at week 8, 24, 40 and End of&#xD;
      Treatment/early termination visits. C reactive protein, Leptin and Adiponectin will be&#xD;
      measured during baseline visit and at end of treatment period. The blood samples taken at&#xD;
      these visits, will be tested for possible biomarkers. TSH, T3 and T4 will be measured during&#xD;
      the screening visit. beta-hCG in women of childbearing potential will be performed during the&#xD;
      screening visit. A serum sample will be collected and kept frozen until study end in case&#xD;
      special investigation needs to be performed. This sample will be collected during the&#xD;
      screening and visit 10/Early Termination.&#xD;
&#xD;
        -  Body weight and waist circumference will be measured in screening, baseline, week 24,&#xD;
           end of treatment and week 65 visits. Height will be measured during the screening visit.&#xD;
&#xD;
        -  ECG will be performed during the screening visit, visit 7 (week 24) and end of treatment&#xD;
           visits.&#xD;
&#xD;
        -  All subjects will undergo two NMRS scans, at screening and end of treatment visits.&#xD;
&#xD;
        -  FibroMax test will be performed only if the investigator thinks it is necessary&#xD;
&#xD;
        -  Liver biopsy will be conducted during the screening and end of treatment visit. The&#xD;
           biopsy in the screening visit will be performed only if it was not done within the 6&#xD;
           months prior to this visit.&#xD;
&#xD;
        -  Metabolomics blood test will be performed at the screening, visit 7 and the&#xD;
           End-of-Treatment/Early Termination visits. From some consenting patients (about 15) a&#xD;
           sample from the liver biopsy will be taken for analysis.&#xD;
&#xD;
        -  Endothelial Function will be conducted in selected sites. The test will be conducted&#xD;
           during the baseline visit before the study treatment will be given and End of&#xD;
           Treatment/early termination visit.&#xD;
&#xD;
        -  Blood sample for Aramchol trough level will be collected (pre-dose) from patients in&#xD;
           Israel at baseline (visit 2) week 4 (visit 4), week 12 (visit 6), week 24 (visit 7),&#xD;
           week 40 (visit 9), end of treatment (visit 10) and follow up (visit 11). At selected&#xD;
           sites in Mexico, USA and Hong Kong one blood sample will be collected (pre-dose) on&#xD;
           visit 4 (up to 10 subjects per country) to test for trough Aramchol blood level&#xD;
           differences between populations (e.g., African American, Asian, Hispanic).&#xD;
&#xD;
        -  Blood sample for gene analysis will be taken from all consenting patients during the&#xD;
           baseline visit, will be kept frozen and analyzed only at the study end.&#xD;
&#xD;
        -  Life style questionnaire will be completed at all visits.&#xD;
&#xD;
        -  Adverse events will be monitored throughout the study.&#xD;
&#xD;
        -  Concomitant Medications will be monitored throughout the study.&#xD;
&#xD;
        -  Telephone contacts will be performed on week 16, 20, 28, 36, 44 and 48. An interim&#xD;
           safety analysis will be conducted as soon as 120 subjects will completed the follow up&#xD;
           period of 24 weeks under study treatment. An independent DSMB will analyze the safety&#xD;
           data and recommend a continued course of action. All patients will continue to be&#xD;
           treated under the study protocol until conclusion of the analysis will be known.&#xD;
&#xD;
      Safety assessment will include frequency and severity of treatment-emergent AEs, clinically&#xD;
      significant laboratory abnormalities, ECG changes and physical examination findings.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2015</start_date>
  <completion_date type="Actual">May 22, 2018</completion_date>
  <primary_completion_date type="Actual">May 22, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Liver Fat</measure>
    <time_frame>At screening (baseline) and at week 52</time_frame>
    <description>absolute % change from baseline to end of study in liver triglycerides to water ratio (fat/water+fat) as measured by MRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NASH Resolution Without Worsening of Fibrosis</measure>
    <time_frame>At screening and at week 52</time_frame>
    <description>The endpoint was defined as end of study biopsy, observed under microscope and showing:&#xD;
Cell Ballooning (special form of liver cell injury associated with cell swelling and enlargement)= 0&#xD;
Inflammation (presence or absence of cells from the immune system) = 0 or 1&#xD;
No worsening of fibrosis (scar formation) = increase in fibrosis score by 1 or more point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis Improvement Without Worsening of NASH</measure>
    <time_frame>At screening and at week 52</time_frame>
    <description>The endpoint was defined as end of study biopsy showing:&#xD;
A decrease in fibrosis score ≥ 1 point&#xD;
No worsening of NASH (defined by an increase of inflammation and/or ballooning)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52/Termination in ALT</measure>
    <time_frame>At baseline until week 52</time_frame>
    <description>Change from baseline to Week 52 or Termination visit in ALT levels (U/L)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline to Termination/Early Termination in HbA1C</measure>
    <time_frame>At baseline until week 52</time_frame>
    <description>Change from baseline to Week 52 or Termination visit in Hemoglobin A1C (%)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">247</enrollment>
  <condition>Fatty Liver</condition>
  <condition>Non-Alcoholic Steatohepatitis</condition>
  <condition>Liver Diseases</condition>
  <condition>Liver Fibroses</condition>
  <arm_group>
    <arm_group_label>Aramchol 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aramchol 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two tablet of Aramchol matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aramchol</intervention_name>
    <description>Subjects will be administered Aramchol as follows:&#xD;
One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.&#xD;
One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.&#xD;
Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml).&#xD;
Subjects are allowed to omit study drugs up to 3 consecutive days during the study.</description>
    <arm_group_label>Aramchol 400mg</arm_group_label>
    <arm_group_label>Aramchol 600mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female age 18 to 75 years.&#xD;
&#xD;
          2. BMI between 25kg/m2 to 40kg/m2 or waist circumference between 88 cm to 200 cm for&#xD;
             women, and between 102 cm to 200 cm for men. If there is deviation above the upper&#xD;
             limit, please consult the MRI center, to ensure that the machine is suitable for the&#xD;
             patient.&#xD;
&#xD;
          3. Known type II Diabetes Mellitus or pre-Diabetes according to American Diabetes&#xD;
             Association. One of the following 3 criteria is needed for pre-Diabetes: Fasting&#xD;
             Plasma Glucose &gt; 100mg/dl (5.5 mmol/l) or 2hPG following 75g OGTT &gt; 140 (7.8 mmol/l)&#xD;
             mg/dl or HbA1c &gt; 5.7%. HbA1c can be repeated at Investigator's discretion.&#xD;
&#xD;
          4. Histologically proven Steatohepatitis on a diagnostic liver biopsy performed either&#xD;
             during screening or within 6 months before screening visit, confirmed by central&#xD;
             laboratory reading of the slides.(Steatosis ≥1 + inflammation ≥1 + ballooning&#xD;
             ≥1).Total activity NAS score of 4 or more.&#xD;
&#xD;
          5. Liver fat concentration in the liver of 5.5% or more as measured by NMRS.&#xD;
&#xD;
          6. Biopsies with an activity NAS score of 4 or more.&#xD;
&#xD;
          7. Normal synthetic liver function (serum albumin &gt;3.2g/dl, INR 0.8-1.2, conjugated&#xD;
             bilirubin &lt; 35 µmol/L).&#xD;
&#xD;
          8. Understanding the nature of the study and signature of the written informed consent.&#xD;
&#xD;
          9. Negative pregnancy test at study entry for females of child bearing potential.&#xD;
&#xD;
         10. Females of child bearing potential practicing reliable contraception throughout the&#xD;
             study period (including oral contraceptives) as well as negative pregnancy test at&#xD;
             study entry.&#xD;
&#xD;
         11. Hypertensive patients must be well controlled by stable dose of anti-hypertensive&#xD;
             medication for at least 2 months prior to screening.&#xD;
&#xD;
         12. Patients previously treated with vitamin E (&gt;400IU/day), Polyunsaturated fatty acid&#xD;
             (&gt;2g/day) or Ursodeoxycholic acid or fish oil can be included if stopped or at least&#xD;
             maintained on stable dose at least 3 months prior to diagnostic liver biopsy (and are&#xD;
             not started during the trial). These treatments-dosages are allowed if they were&#xD;
             stable for at least 12 months prior to biopsy and can remain stable throughout the&#xD;
             study. (Dosages less than the amounts stated above are allowed without washout- or&#xD;
             stable-period restrictions).&#xD;
&#xD;
         13. For patients with type II Diabetes, glycaemia must be controlled (Glycosylated&#xD;
             Hemoglobin A1c ≤9%) while any HbA1c change should not exceed 1.5% during 6 months&#xD;
             prior to enrolment). Treatments with anti-diabetic medications (except for those&#xD;
             mentioned in Exclusion 16) are permitted if glycaemia is self-monitored by the&#xD;
             patient. HbA1c can be repeated at Investigator's discretion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with other active (acute or chronic) liver disease other than NASH (e.g.&#xD;
             viral hepatitis, unless eradicated at least 3 years prior to screening; genetic&#xD;
             hemochromatosis; Wilson disease; alpha 1antitripsin deficiency; alcohol liver disease;&#xD;
             drug-induced liver disease) at the time of randomization.&#xD;
&#xD;
          2. Patients with clinically or histologically documented liver cirrhosis&#xD;
&#xD;
          3. Known alcohol and/or any other drug abuse or dependence in the last five years.&#xD;
&#xD;
          4. Known history or presence of clinically significant cardiovascular, gastrointestinal,&#xD;
             metabolic other than Diabetes Mellitus, neurologic, pulmonary, endocrine, psychiatric,&#xD;
             neoplastic disorder or nephrotic syndrome, that in the opinion of the Investigator&#xD;
             warrant exclusion from the study.&#xD;
&#xD;
          5. Patients with familial (i.e., genetic) hypertriglyceridemia and familial (i.e.,&#xD;
             genetic) hypercholesterolemia.&#xD;
&#xD;
          6. History or presence of any disease or condition known to interfere with the absorption&#xD;
             distribution, metabolism or excretion of drugs including bile salt metabolites (e.g.&#xD;
             inflammatory bowel disease (IBD)), previous intestinal (ileal or colonic) operation,&#xD;
             chronic pancreatitis, celiac disease or previous vagotomy. Ongoing Chronic&#xD;
             constipation&#xD;
&#xD;
          7. Patients with heart or brain pacemaker (i.e., implantable neurological devices).&#xD;
&#xD;
          8. Surgery during the last three month before screening which involved stent implantation&#xD;
             of metal devices (e.g. knee, hip etc.)&#xD;
&#xD;
          9. Weight loss of more than 5% within 6 months prior to randomization.&#xD;
&#xD;
         10. History of bariatric surgery within 5 years of liver biopsy.&#xD;
&#xD;
         11. Uncontrolled arterial hypertension.&#xD;
&#xD;
         12. Women who are pregnant and breast feeding.&#xD;
&#xD;
         13. Diabetes Mellitus other than type II (type I, endocrinopathy, genetic syndromes etc.).&#xD;
&#xD;
         14. Patients with HIV infection.&#xD;
&#xD;
         15. Daily alcohol intake &gt;20 g/day for women and &gt;30 g/day for men (on average per day) as&#xD;
             per medical history.&#xD;
&#xD;
         16. Treatment with other anti-diabetic medications:&#xD;
&#xD;
             GLP-1 receptor agonists and Thiazolidinediones (TZDs), unless started at least 12&#xD;
             months prior to biopsy and on stable dose for 6 months. In case of GLP-1 receptor&#xD;
             agonists stopped, it should be at least 6 months before biopsy as per medical history.&#xD;
&#xD;
         17. SGLT-2 Inhibitors, Metformin, fibrates, statins, insulin, DPP-4 inhibitors and&#xD;
             sulfonylurea unless prescribed dose has been stable for the last 6 months prior to the&#xD;
             biopsy.&#xD;
&#xD;
         18. Treatment with Valproic acid, Tamoxifen, Methotrexate, Amiodarone or chronic treatment&#xD;
             with anti-cholinergic agents, corticosteroids, high dose estrogen and tetracycline&#xD;
             within 12 months prior to the screening visit.&#xD;
&#xD;
         19. Chronic treatment with antibiotics (e.g. Rifaximin).&#xD;
&#xD;
         20. Homeopathic and/or alternative treatments. Any treatment should be stopped during the&#xD;
             screening period at least 48 hours before randomization.&#xD;
&#xD;
         21. Uncontrolled hypothyroidism defined as Thyroid Stimulating hormone &gt;2X the upper limit&#xD;
             of normal (ULN). Thyroid dysfunction controlled for at least 6 months prior to&#xD;
             screening is permitted.&#xD;
&#xD;
         22. Patients with renal dysfunction eGFR&lt; 40.&#xD;
&#xD;
         23. Unexplained serum creatine phosphokinase (CPK) &gt;3X the upper limit of normal (UNL).&#xD;
             Patients with a reason for CPK elevation may have the measurement repeated prior to&#xD;
             randomization; a CPK retest &gt; 3X ULN leads to exclusion.&#xD;
&#xD;
         24. Patients with condition(s) that makes them unsuitable to perform the NMRS (as&#xD;
             determined by the PI or the MRI facility).&#xD;
&#xD;
         25. Hypersensitivity to Aramchol or to any of the excipients in the tablets&#xD;
&#xD;
         26. Hypersensitivity to cholic acid or bile acid sequestrants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vlad Ratziu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Hepatology, Université Pierre et Marie Curie &amp; Hospital Pitie Salpetriere Medical University, Paris.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institue for Clinical Research Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Liver Research Institute</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Empoire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Department of Medicine Division of Gastroenterology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Consultants of San Antonio</name>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Medical Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedica Research Group</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica CEIC</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universidad de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clinicas Vina del Mar</name>
      <address>
        <city>Vina del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Joseph Service Hepato Gastro Entrologie</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Centre Hospiatalier Universitaire de Rennes</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Saint-Antoine AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unimed Adjara</name>
      <address>
        <city>Batumi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Cortex</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Tatishvili Medical Center</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD Diacor</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Clinical Medicine</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EUGASTRO GmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitat Leipzig Medizinische Fakultat</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humanity &amp; Health Medical Centre</name>
      <address>
        <city>Central</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Medical Cente</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naharia Medical Center</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Holy family Medical Center</name>
      <address>
        <city>Nazareth</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Saurasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asaf Harofeh Medical Center</name>
      <address>
        <city>Zrifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. San Paolo</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. U. &quot;Federico II&quot; di Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale &quot;A.Cardarelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospidaliera Universitaria Seconda Universita di Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Ospedale Cristo Re&quot; dell'Istituto Figlie di N.S. al Monte Calvario</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico di Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Camillo</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I Di Roma</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Univestitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kaunas Clinics</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaipeda University Hospital</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilinius University Hospital Santariskiu Klinikos</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Hígado Hospital Universitario Dr. José Eleuterio González</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JM Research</name>
      <address>
        <city>Cuernavaca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Médico</name>
      <address>
        <city>Metepec</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torre de Consultorios Clinica Londres</name>
      <address>
        <city>Mexico City</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Medico</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Ciencias Medicas y de la Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torre de Consultorios Clinica Londres</name>
      <address>
        <city>Mexico Distrito Federal</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelerium Clinical Research</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Medico del Dr. Mauricio Castillo Barradas</name>
      <address>
        <city>México Distrito Federal</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Angeles Valle oriente&quot; Hospital</name>
      <address>
        <city>San Pedro Garza Garcia</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Institute Colentina</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The National Institute for Infectious Diseases &quot;Prof. Dr. Matei Bals&quot;, Clinical Department for Adults II</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cluj County Emergency Hospital</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400013</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TVM Medical</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400013</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Hospital Mures-Gastroenterology Department</name>
      <address>
        <city>Targu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Colombia</country>
    <country>Peru</country>
  </removed_countries>
  <link>
    <url>http://www.cghjournal.org/article/S1542-3565(14)00673-9/pdf</url>
    <description>The Fatty Acid-Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <results_first_submitted>May 31, 2021</results_first_submitted>
  <results_first_submitted_qc>June 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 14, 2021</results_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NASH</keyword>
  <keyword>fibroses</keyword>
  <keyword>obesity</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02279524/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aramchol 600mg</title>
          <description>One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg, once a day for 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>Aramchol 400mg</title>
          <description>One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol, once a day for 52 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Two tablets of matching placebo for Aramchol, once a day for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disallowed medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Bariatric surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aramchol 600mg</title>
          <description>One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.</description>
        </group>
        <group group_id="B2">
          <title>Aramchol 400mg</title>
          <description>One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Two tablet of Aramchol matching placebo.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="48"/>
            <count group_id="B4" value="247"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.9" spread="9.8"/>
                    <measurement group_id="B2" value="53.9" spread="10.9"/>
                    <measurement group_id="B3" value="54.4" spread="10.3"/>
                    <measurement group_id="B4" value="54.4" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latin American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latin Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed (Martinican)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m^2) at Screening</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="4.2"/>
                    <measurement group_id="B2" value="32.4" spread="4.5"/>
                    <measurement group_id="B3" value="32.6" spread="4.9"/>
                    <measurement group_id="B4" value="32.7" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Liver Fat</title>
        <description>absolute % change from baseline to end of study in liver triglycerides to water ratio (fat/water+fat) as measured by MRS</description>
        <time_frame>At screening (baseline) and at week 52</time_frame>
        <population>Pre-defined FASmri analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aramchol 600mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.</description>
          </group>
          <group group_id="O2">
            <title>Aramchol 400mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Two tablet of Aramchol matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Liver Fat</title>
          <description>absolute % change from baseline to end of study in liver triglycerides to water ratio (fat/water+fat) as measured by MRS</description>
          <population>Pre-defined FASmri analysis set</population>
          <units>Abs. % Change from Baseline Liver Fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.18" spread="1.01"/>
                    <measurement group_id="O2" value="-3.41" spread="0.96"/>
                    <measurement group_id="O3" value="-0.09" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0655</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-3.09</param_value>
            <ci_percent>1.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>Post-Hoc Responder Analysis - was also carried out. See Post-Hoc analysis</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0450</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-3.32</param_value>
            <ci_percent>1.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>Post-Hoc Responder Analysis - was also carried out. See Post-Hoc analysis</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NASH Resolution Without Worsening of Fibrosis</title>
        <description>The endpoint was defined as end of study biopsy, observed under microscope and showing:&#xD;
Cell Ballooning (special form of liver cell injury associated with cell swelling and enlargement)= 0&#xD;
Inflammation (presence or absence of cells from the immune system) = 0 or 1&#xD;
No worsening of fibrosis (scar formation) = increase in fibrosis score by 1 or more point</description>
        <time_frame>At screening and at week 52</time_frame>
        <population>FASBiopsy analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aramchol 600mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.</description>
          </group>
          <group group_id="O2">
            <title>Aramchol 400mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Two tablet of Aramchol matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>NASH Resolution Without Worsening of Fibrosis</title>
          <description>The endpoint was defined as end of study biopsy, observed under microscope and showing:&#xD;
Cell Ballooning (special form of liver cell injury associated with cell swelling and enlargement)= 0&#xD;
Inflammation (presence or absence of cells from the immune system) = 0 or 1&#xD;
No worsening of fibrosis (scar formation) = increase in fibrosis score by 1 or more point</description>
          <population>FASBiopsy analysis set</population>
          <units>% of subjects reaching the end-point</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="7.5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0514</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The method used was a Baseline Adjusted Logistic Regression</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>22.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4955</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>9.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fibrosis Improvement Without Worsening of NASH</title>
        <description>The endpoint was defined as end of study biopsy showing:&#xD;
A decrease in fibrosis score ≥ 1 point&#xD;
No worsening of NASH (defined by an increase of inflammation and/or ballooning)</description>
        <time_frame>At screening and at week 52</time_frame>
        <population>Predefined FASBiopsy analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aramchol 600mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.</description>
          </group>
          <group group_id="O2">
            <title>Aramchol 400mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Two tablet of Aramchol matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Fibrosis Improvement Without Worsening of NASH</title>
          <description>The endpoint was defined as end of study biopsy showing:&#xD;
A decrease in fibrosis score ≥ 1 point&#xD;
No worsening of NASH (defined by an increase of inflammation and/or ballooning)</description>
          <population>Predefined FASBiopsy analysis set</population>
          <units>% of subjects reaching the end-point</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5"/>
                    <measurement group_id="O2" value="21.3"/>
                    <measurement group_id="O3" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2110</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>5.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8425</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>3.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52/Termination in ALT</title>
        <description>Change from baseline to Week 52 or Termination visit in ALT levels (U/L)</description>
        <time_frame>At baseline until week 52</time_frame>
        <population>Pre-defined FASALT analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aramchol 600mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.</description>
          </group>
          <group group_id="O2">
            <title>Aramchol 400mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Two tablet of Aramchol matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52/Termination in ALT</title>
          <description>Change from baseline to Week 52 or Termination visit in ALT levels (U/L)</description>
          <population>Pre-defined FASALT analysis set</population>
          <units>U/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.3" spread="3.7"/>
                    <measurement group_id="O2" value="-12.0" spread="3.6"/>
                    <measurement group_id="O3" value="11.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-29.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.4</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-23.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.3</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline to Termination/Early Termination in HbA1C</title>
        <description>Change from baseline to Week 52 or Termination visit in Hemoglobin A1C (%)</description>
        <time_frame>At baseline until week 52</time_frame>
        <population>Analysis Set: FASHgA1C</population>
        <group_list>
          <group group_id="O1">
            <title>Aramchol 600mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.</description>
          </group>
          <group group_id="O2">
            <title>Aramchol 400mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Two tablet of Aramchol matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Termination/Early Termination in HbA1C</title>
          <description>Change from baseline to Week 52 or Termination visit in Hemoglobin A1C (%)</description>
          <population>Analysis Set: FASHgA1C</population>
          <units>% of HbA1C</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1268" spread="0.0769"/>
                    <measurement group_id="O2" value="-0.0417" spread="0.0754"/>
                    <measurement group_id="O3" value="0.3202" spread="0.1089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-0.4470</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7063</ci_lower_limit>
            <ci_upper_limit>-0.1877</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0061</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-0.3620</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6196</ci_lower_limit>
            <ci_upper_limit>-0.1043</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline to Week 52/Termination in AST</title>
        <description>Change from baseline to Week 52 or termination visit in AST levels (U/L)</description>
        <time_frame>At baseline until week 52</time_frame>
        <population>FASAST Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Aramchol 600mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.</description>
          </group>
          <group group_id="O2">
            <title>Aramchol 400mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Two tablet of Aramchol matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52/Termination in AST</title>
          <description>Change from baseline to Week 52 or termination visit in AST levels (U/L)</description>
          <population>FASAST Analysis Set</population>
          <units>U/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.83" spread="2.49"/>
                    <measurement group_id="O2" value="-7.21" spread="2.42"/>
                    <measurement group_id="O3" value="6.68" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-17.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.2</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-13.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.2</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change From Baseline in Mean Liver Fat - Responder Analysis</title>
        <description>A responder is defined according to &gt;5% absolute improvement from baseline. A cutoff of 5% absolute reduction in liver F/(F+W) ratio was used as a surrogate for potentially clinically meaningful MRI reduction.</description>
        <time_frame>Baseline to 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aramchol 600mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.</description>
          </group>
          <group group_id="O2">
            <title>Aramchol 400mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Two tablet of Aramchol matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Liver Fat - Responder Analysis</title>
          <description>A responder is defined according to &gt;5% absolute improvement from baseline. A cutoff of 5% absolute reduction in liver F/(F+W) ratio was used as a surrogate for potentially clinically meaningful MRI reduction.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0"/>
                    <measurement group_id="O2" value="36.7"/>
                    <measurement group_id="O3" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0279</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>6.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0878</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>5.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Progression to Cirrhosis</title>
        <description>Fibrosis stage 4 in liver biopsy</description>
        <time_frame>Week 52</time_frame>
        <population>This analysis is limited by low number of events, and the duration of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Aramchol 600mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.</description>
          </group>
          <group group_id="O2">
            <title>Aramchol 400mg</title>
            <description>One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Two tablet of Aramchol matching placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression to Cirrhosis</title>
          <description>Fibrosis stage 4 in liver biopsy</description>
          <population>This analysis is limited by low number of events, and the duration of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1008</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
            <estimate_desc>This analysis is limited by low number of events, and the duration of the study.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5693</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>3.05</ci_upper_limit>
            <estimate_desc>This analysis is limited by low number of events, and the duration of the study.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks + 13 weeks follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aramchol 600mg</title>
          <description>One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.</description>
        </group>
        <group group_id="E2">
          <title>Aramchol 400mg</title>
          <description>One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Two tablet of Aramchol matching placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Mammogram abnorma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar radiculopathy .</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary emboli</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Shoulder operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Consistent with scientific standards, publication of the results of the study shall be made only as part of a publication of the results obtained by all sites performing the protocol.&#xD;
Investigators who wish to publish the results, must provide Galmed with a manuscript for review 60 (sixty) days prior to submission for publication.&#xD;
Galmed retains the right to delete confidential and proprietary information and to object suggested publication and/or its timing (at the Company's sole discretion).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Galmed Research and Development, Ltd.</organization>
      <phone>+972.3.693.8448</phone>
      <email>clinicaltrial@galmedpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

